ID   ABL1_HUMAN              Reviewed;        1130 AA.
AC   P00519; A3KFJ3; Q13869; Q13870; Q16133; Q17R61; Q45F09;
DT   21-JUL-1986, integrated into UniProtKB/Swiss-Prot.
DT   24-JAN-2006, sequence version 4.
DT   02-NOV-2010, entry version 163.
DE   RecName: Full=Tyrosine-protein kinase ABL1;
DE            EC=2.7.10.2;
DE   AltName: Full=Abelson murine leukemia viral oncogene homolog 1;
DE   AltName: Full=Proto-oncogene c-Abl;
DE   AltName: Full=p150;
GN   Name=ABL1; Synonyms=ABL, JTK7;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM IA), ALTERNATIVE SPLICING, AND
RP   VARIANT PRO-140.
RX   MEDLINE=87028219; PubMed=3021337; DOI=10.1016/0092-8674(86)90450-2;
RA   Shtivelman E., Lifshitz B., Gale R.P., Roe B.A., Canaani E.;
RT   "Alternative splicing of RNAs transcribed from the human abl gene and
RT   from the bcr-abl fused gene.";
RL   Cell 47:277-284(1986).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM IA).
RC   TISSUE=Fibroblast;
RX   MEDLINE=90082420; PubMed=2687768;
RA   Fainstein E., Einat M., Gokkel E., Marcelle C., Croce C.M., Gale R.P.,
RA   Canaani E.;
RT   "Nucleotide sequence analysis of human abl and bcr-abl cDNAs.";
RL   Oncogene 4:1477-1481(1989).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORMS IA AND IB).
RC   TISSUE=Lung;
RX   MEDLINE=95394474; PubMed=7665185; DOI=10.1006/geno.1995.1008;
RA   Chissoe S.L., Bodenteich A., Wang Y.-F., Wang Y.-P., Burian D.,
RA   Clifton S.W., Crabtree J., Freeman A., Iyer K., Jian L., Ma Y.,
RA   McLaury H.-J., Pan H.-Q., Sarhan O.H., Toth S., Wang Z., Zhang G.,
RA   Heisterkamp N., Groffen J., Roe B.A.;
RT   "Sequence and analysis of the human ABL gene, the BCR gene, and
RT   regions involved in the Philadelphia chromosomal translocation.";
RL   Genomics 27:67-82(1995).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS VAL-706; PRO-852;
RP   SER-900 AND LEU-972.
RG   NIEHS SNPs program;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15164053; DOI=10.1038/nature02465;
RA   Humphray S.J., Oliver K., Hunt A.R., Plumb R.W., Loveland J.E.,
RA   Howe K.L., Andrews T.D., Searle S., Hunt S.E., Scott C.E., Jones M.C.,
RA   Ainscough R., Almeida J.P., Ambrose K.D., Ashwell R.I.S.,
RA   Babbage A.K., Babbage S., Bagguley C.L., Bailey J., Banerjee R.,
RA   Barker D.J., Barlow K.F., Bates K., Beasley H., Beasley O., Bird C.P.,
RA   Bray-Allen S., Brown A.J., Brown J.Y., Burford D., Burrill W.,
RA   Burton J., Carder C., Carter N.P., Chapman J.C., Chen Y., Clarke G.,
RA   Clark S.Y., Clee C.M., Clegg S., Collier R.E., Corby N., Crosier M.,
RA   Cummings A.T., Davies J., Dhami P., Dunn M., Dutta I., Dyer L.W.,
RA   Earthrowl M.E., Faulkner L., Fleming C.J., Frankish A.,
RA   Frankland J.A., French L., Fricker D.G., Garner P., Garnett J.,
RA   Ghori J., Gilbert J.G.R., Glison C., Grafham D.V., Gribble S.,
RA   Griffiths C., Griffiths-Jones S., Grocock R., Guy J., Hall R.E.,
RA   Hammond S., Harley J.L., Harrison E.S.I., Hart E.A., Heath P.D.,
RA   Henderson C.D., Hopkins B.L., Howard P.J., Howden P.J., Huckle E.,
RA   Johnson C., Johnson D., Joy A.A., Kay M., Keenan S., Kershaw J.K.,
RA   Kimberley A.M., King A., Knights A., Laird G.K., Langford C.,
RA   Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C., Lloyd D.M.,
RA   Lovell J., Martin S., Mashreghi-Mohammadi M., Matthews L., McLaren S.,
RA   McLay K.E., McMurray A., Milne S., Nickerson T., Nisbett J.,
RA   Nordsiek G., Pearce A.V., Peck A.I., Porter K.M., Pandian R.,
RA   Pelan S., Phillimore B., Povey S., Ramsey Y., Rand V., Scharfe M.,
RA   Sehra H.K., Shownkeen R., Sims S.K., Skuce C.D., Smith M.,
RA   Steward C.A., Swarbreck D., Sycamore N., Tester J., Thorpe A.,
RA   Tracey A., Tromans A., Thomas D.W., Wall M., Wallis J.M., West A.P.,
RA   Whitehead S.L., Willey D.L., Williams S.A., Wilming L., Wray P.W.,
RA   Young L., Ashurst J.L., Coulson A., Blocker H., Durbin R.M.,
RA   Sulston J.E., Hubbard T., Jackson M.J., Bentley D.R., Beck S.,
RA   Rogers J., Dunham I.;
RT   "DNA sequence and analysis of human chromosome 9.";
RL   Nature 429:369-374(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM IB).
RC   TISSUE=Cerebellum;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 27-40, AND SUBCELLULAR COMPONENT.
RX   MEDLINE=88065859; PubMed=2825022; DOI=10.1038/330386a0;
RA   Fainstein E., Marcelle C., Rosner A., Canaani E., Gale R.P.,
RA   Dreazen O., Smith S.D., Croce C.M.;
RT   "A new fused transcript in Philadelphia chromosome positive acute
RT   lymphocytic leukaemia.";
RL   Nature 330:386-388(1987).
RN   [9]
RP   NUCLEOTIDE SEQUENCE OF 360-426.
RX   MEDLINE=83245023; PubMed=6191223; DOI=10.1038/304167a0;
RA   Groffen J., Heisterkamp N., Reynolds F.H. Jr., Stephenson J.R.;
RT   "Homology between phosphotyrosine acceptor site of human c-abl and
RT   viral oncogene products.";
RL   Nature 304:167-169(1983).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 825-845.
RX   MEDLINE=94142331; PubMed=7545908;
RA   Inokuchi K., Futaki M., Dan K., Nomura T.;
RT   "Sequence analysis of the mutation at codon 834 and the sequence
RT   variation of codon 837 of c-abl gene.";
RL   Leukemia 8:343-344(1994).
RN   [11]
RP   MYRISTOYLATION (ISOFORM IB).
RX   PubMed=2542016;
RA   Jackson P., Baltimore D.;
RT   "N-terminal mutations activate the leukemogenic potential of the
RT   myristoylated form of c-abl.";
RL   EMBO J. 8:449-456(1989).
RN   [12]
RP   INTERACTION WITH RIN1, AND FUNCTION.
RX   MEDLINE=97289700; PubMed=9144171; DOI=10.1073/pnas.94.10.4954;
RA   Han L., Wong D., Dhaka A., Afar D.E.H., White M., Xie W.,
RA   Herschman H., Witte O., Colicelli J.;
RT   "Protein binding and signaling properties of RIN1 suggest a unique
RT   effector function.";
RL   Proc. Natl. Acad. Sci. U.S.A. 94:4954-4959(1997).
RN   [13]
RP   INTERACTION WITH INPPL1.
RX   PubMed=10194451;
RA   Wisniewski D., Strife A., Swendeman S., Erdjument-Bromage H.,
RA   Geromanos S., Kavanaugh W.M., Tempst P., Clarkson B.;
RT   "A novel SH2-containing phosphatidylinositol 3,4,5-trisphosphate 5-
RT   phosphatase (SHIP2) is constitutively tyrosine phosphorylated and
RT   associated with src homologous and collagen gene (SHC) in chronic
RT   myelogenous leukemia progenitor cells.";
RL   Blood 93:2707-2720(1999).
RN   [14]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-185; TYR-226; TYR-253;
RP   TYR-257; TYR-264; TYR-393; THR-394 AND TYR-469, AND MASS SPECTROMETRY.
RX   MEDLINE=22426906; PubMed=12522270; DOI=10.1073/pnas.2436191100;
RA   Salomon A.R., Ficarro S.B., Brill L.M., Brinker A., Phung Q.T.,
RA   Ericson C., Sauer K., Brock A., Horn D.M., Schultz P.G., Peters E.C.;
RT   "Profiling of tyrosine phosphorylation pathways in human cells using
RT   mass spectrometry.";
RL   Proc. Natl. Acad. Sci. U.S.A. 100:443-448(2003).
RN   [15]
RP   INTERACTION WITH SORBS1.
RX   MEDLINE=21269187; PubMed=11374898; DOI=10.1006/geno.2001.6541;
RA   Lin W.-H., Huang C.-J., Liu M.-W., Chang H.-M., Chen Y.-J., Tai T.-Y.,
RA   Chuang L.-M.;
RT   "Cloning, mapping, and characterization of the human sorbin and SH3
RT   domain containing 1 (SORBS1) gene: a protein associated with c-Abl
RT   during insulin signaling in the hepatoma cell line Hep3B.";
RL   Genomics 74:12-20(2001).
RN   [16]
RP   INTERACTION WITH YWHAB; YWHAE; YWHAG; YWHAH; SFN AND YWHAZ,
RP   PHOSPHORYLATION AT THR-735, MASS SPECTROMETRY, SUBCELLULAR LOCATION,
RP   AND MUTAGENESIS OF THR-735.
RX   PubMed=15696159; DOI=10.1038/ncb1228;
RA   Yoshida K., Yamaguchi T., Natsume T., Kufe D., Miki Y.;
RT   "JNK phosphorylation of 14-3-3 proteins regulates nuclear targeting of
RT   c-Abl in the apoptotic response to DNA damage.";
RL   Nat. Cell Biol. 7:278-285(2005).
RN   [17]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-569; SER-683; SER-805;
RP   SER-809 AND SER-949, AND MASS SPECTROMETRY.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P.,
RA   Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in
RT   signaling networks.";
RL   Cell 127:635-648(2006).
RN   [18]
RP   FUNCTION, AND INTERACTION WITH PSMA7.
RX   PubMed=16678104; DOI=10.1016/j.molcel.2006.04.007;
RA   Liu X., Huang W., Li C., Li P., Yuan J., Li X., Qiu X.B., Ma Q.,
RA   Cao C.;
RT   "Interaction between c-Abl and Arg tyrosine kinases and proteasome
RT   subunit PSMA7 regulates proteasome degradation.";
RL   Mol. Cell 22:317-327(2006).
RN   [19]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-185, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Lung carcinoma;
RX   PubMed=18083107; DOI=10.1016/j.cell.2007.11.025;
RA   Rikova K., Guo A., Zeng Q., Possemato A., Yu J., Haack H., Nardone J.,
RA   Lee K., Reeves C., Li Y., Hu Y., Tan Z., Stokes M., Sullivan L.,
RA   Mitchell J., Wetzel R., Macneill J., Ren J.M., Yuan J.,
RA   Bakalarski C.E., Villen J., Kornhauser J.M., Smith B., Li D., Zhou X.,
RA   Gygi S.P., Gu T.-L., Polakiewicz R.D., Rush J., Comb M.J.;
RT   "Global survey of phosphotyrosine signaling identifies oncogenic
RT   kinases in lung cancer.";
RL   Cell 131:1190-1203(2007).
RN   [20]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-569, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Leukemic T-cell;
RX   PubMed=17192257; DOI=10.1074/mcp.T600062-MCP200;
RA   Wissing J., Jaensch L., Nimtz M., Dieterich G., Hornberger R.,
RA   Keri G., Wehland J., Daub H.;
RT   "Proteomics analysis of protein kinases by target class-selective
RT   prefractionation and tandem mass spectrometry.";
RL   Mol. Cell. Proteomics 6:537-547(2007).
RN   [21]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-50; TYR-185; TYR-393;
RP   SER-569; THR-613; SER-620; SER-659; SER-683; SER-718; THR-781;
RP   SER-805; SER-809; THR-814; THR-844; THR-852; SER-917; SER-919; SER-936
RP   AND SER-977, AND MASS SPECTROMETRY.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of
RT   the kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [22]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-569; THR-844; THR-852
RP   AND SER-917, AND MASS SPECTROMETRY.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [23]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-805; SER-809; THR-852
RP   AND SER-855, AND MASS SPECTROMETRY.
RC   TISSUE=Embryonic kidney;
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [24]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-392; TYR-393 AND
RP   SER-569, AND MASS SPECTROMETRY.
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [25]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-50 AND SER-569, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [26]
RP   STRUCTURE BY NMR OF SH2 DOMAIN.
RX   MEDLINE=92370689; PubMed=1505033; DOI=10.1016/0092-8674(92)90437-H;
RA   Overduin M., Rios C.B., Mayer B.J., Baltimore D., Cowburn D.;
RT   "Three-dimensional solution structure of the src homology 2 domain of
RT   c-abl.";
RL   Cell 70:697-704(1992).
RN   [27]
RP   STRUCTURE BY NMR OF SH2 DOMAIN.
RX   MEDLINE=93101588; PubMed=1281542; DOI=10.1073/pnas.89.24.11673;
RA   Overduin M., Mayer B.J., Rios C.B., Baltimore D., Cowburn D.;
RT   "Secondary structure of Src homology 2 domain of c-Abl by
RT   heteronuclear NMR spectroscopy in solution.";
RL   Proc. Natl. Acad. Sci. U.S.A. 89:11673-11677(1992).
RN   [28]
RP   3D-STRUCTURE MODELING OF SH3 DOMAIN.
RX   MEDLINE=95199229; PubMed=7892170; DOI=10.1002/prot.340200302;
RA   Pisabarro M.T., Ortiz A.R., Serrano L., Wade R.C.;
RT   "Homology modeling of the Abl-SH3 domain.";
RL   Proteins 20:203-215(1994).
RN   [29]
RP   STRUCTURE BY NMR OF SH3 DOMAIN.
RX   MEDLINE=96131878; PubMed=8590002; DOI=10.1016/S0969-2126(01)00243-X;
RA   Gosser Y.Q., Zheng J., Overduin M., Mayer B.J., Cowburn D.;
RT   "The solution structure of Abl SH3, and its relationship to SH2 in the
RT   SH(32) construct.";
RL   Structure 3:1075-1086(1995).
RN   [30]
RP   X-RAY CRYSTALLOGRAPHY (1.65 ANGSTROMS) OF 64-121.
RX   MEDLINE=98365516; PubMed=9698566; DOI=10.1006/jmbi.1998.1932;
RA   Pisabarro M.T., Serrano L., Wilmanns M.;
RT   "Crystal structure of the abl-SH3 domain complexed with a designed
RT   high-affinity peptide ligand: implications for SH3-ligand
RT   interactions.";
RL   J. Mol. Biol. 281:513-521(1998).
RN   [31]
RP   STRUCTURE BY NMR OF 62-122 IN COMPLEX WITH CRK.
RX   MEDLINE=22294994; PubMed=12384576; DOI=10.1073/pnas.212518799;
RA   Donaldson L.W., Gish G., Pawson T., Kay L.E., Forman-Kay J.D.;
RT   "Structure of a regulatory complex involving the Abl SH3 domain, the
RT   Crk SH2 domain, and a Crk-derived phosphopeptide.";
RL   Proc. Natl. Acad. Sci. U.S.A. 99:14053-14058(2002).
RN   [32]
RP   X-RAY CRYSTALLOGRAPHY (3.42 ANGSTROMS) OF 27-512, MYRISTOYLATION
RP   (ISOFORM IB), ENZYME REGULATION, AND MASS SPECTROMETRY.
RX   PubMed=12654251;
RA   Nagar B., Hantschel O., Young M.A., Scheffzek K., Veach D.,
RA   Bornmann W., Clarkson B., Superti-Furga G., Kuriyan J.;
RT   "Structural basis for the autoinhibition of c-Abl tyrosine kinase.";
RL   Cell 112:859-871(2003).
RN   [33]
RP   X-RAY CRYSTALLOGRAPHY (1.91 ANGSTROMS) OF 229-513 OF MUTANT PRO-396 IN
RP   COMPLEX WITH INHIBITOR VX-680, FUNCTION, AND ENZYME REGULATION.
RX   PubMed=16424036; DOI=10.1158/0008-5472.CAN-05-2788;
RA   Young M.A., Shah N.P., Chao L.H., Seeliger M., Milanov Z.V.,
RA   Biggs W.H. III, Treiber D.K., Patel H.K., Zarrinkar P.P.,
RA   Lockhart D.J., Sawyers C.L., Kuriyan J.;
RT   "Structure of the kinase domain of an imatinib-resistant Abl mutant in
RT   complex with the Aurora kinase inhibitor VX-680.";
RL   Cancer Res. 66:1007-1014(2006).
RN   [34]
RP   X-RAY CRYSTALLOGRAPHY (2.27 ANGSTROMS) OF 38-512, MASS SPECTROMETRY,
RP   MYRISTOYLATION OF N-TERMINUS (ISOFORM IB), PHOSPHORYLATION AT SER-50,
RP   AUTOINHIBITION MECHANISM, AND ENZYME REGULATION.
RX   PubMed=16543148; DOI=10.1016/j.molcel.2006.01.035;
RA   Nagar B., Hantschel O., Seeliger M., Davies J.M., Weis W.I.,
RA   Superti-Furga G., Kuriyan J.;
RT   "Organization of the SH3-SH2 unit in active and inactive forms of the
RT   c-Abl tyrosine kinase.";
RL   Mol. Cell 21:787-798(2006).
RN   [35]
RP   X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) OF 229-512 IN COMPLEXES WITH
RP   ATP-PEPTIDE CONJUGATE, AND CONFORMATION CHANGES DURING ACTIVATION.
RX   PubMed=16640460; DOI=10.1371/journal.pbio.0040144;
RA   Levinson N.M., Kuchment O., Shen K., Young M.A., Koldobskiy M.,
RA   Karplus M., Cole P.A., Kuriyan J.;
RT   "A Src-like inactive conformation in the abl tyrosine kinase domain.";
RL   PLoS Biol. 4:E144-E144(2006).
RN   [36]
RP   X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS) OF 229-500 IN COMPLEXES WITH
RP   IMANITIB AND WITH THE INHIBITORS NVP-AEG082; NVP-AFN941; NVP-AFG210
RP   AND PD180970.
RX   PubMed=17164530; DOI=10.1107/S0907444906047287;
RA   Cowan-Jacob S.W., Fendrich G., Floersheimer A., Furet P.,
RA   Liebetanz J., Rummel G., Rheinberger P., Centeleghe M., Fabbro D.,
RA   Manley P.W.;
RT   "Structural biology contributions to the discovery of drugs to treat
RT   chronic myelogenous leukaemia.";
RL   Acta Crystallogr. D 63:80-93(2007).
RN   [37]
RP   X-RAY CRYSTALLOGRAPHY (1.75 ANGSTROMS) OF 64-121 OF MUTANT ALA-114 IN
RP   COMPLEX WITH PROLINE-RICH PEPTIDE.
RX   PubMed=17452790; DOI=10.1107/S0907444907011109;
RA   Camara-Artigas A., Palencia A., Martinez J.C., Luque I., Gavira J.A.,
RA   Garcia-Ruiz J.M.;
RT   "Crystallization by capillary counter-diffusion and structure
RT   determination of the N114A mutant of the SH3 domain of Abl tyrosine
RT   kinase complexed with a high-affinity peptide ligand.";
RL   Acta Crystallogr. D 63:646-652(2007).
RN   [38]
RP   X-RAY CRYSTALLOGRAPHY (1.4 ANGSTROMS) OF 60-121 IN COMPLEX WITH
RP   PROLINE-RICH PEPTIDE P41.
RX   PubMed=19906645; DOI=10.1074/jbc.M109.048033;
RA   Palencia A., Camara-Artigas A., Pisabarro M.T., Martinez J.C.,
RA   Luque I.;
RT   "Role of interfacial water molecules in proline-rich ligand
RT   recognition by the Src homology 3 domain of Abl.";
RL   J. Biol. Chem. 285:2823-2833(2010).
RN   [39]
RP   X-RAY CRYSTALLOGRAPHY (1.75 ANGSTROMS) OF 121-232 IN COMPLEX WITH
RP   ANTIBODY MIMIC HA4, FUNCTION, AND CATALYTIC ACTIVITY.
RX   PubMed=20357770; DOI=10.1038/nsmb.1793;
RA   Wojcik J., Hantschel O., Grebien F., Kaupe I., Bennett K.L.,
RA   Barkinge J., Jones R.B., Koide A., Superti-Furga G., Koide S.;
RT   "A potent and highly specific FN3 monobody inhibitor of the Abl SH2
RT   domain.";
RL   Nat. Struct. Mol. Biol. 17:519-527(2010).
RN   [40]
RP   VARIANTS GLY-47; LYS-166; VAL-706; LEU-810 AND LEU-972.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Protein kinase that regulates key processes linked to
CC       cell growth and survival. Regulates cytoskeleton remodeling during
CC       cell differentiation, cell division and cell adhesion. Localizes
CC       to dynamic actin structures, and phosphorylates CRK and CRKL,
CC       DOK1, and other proteins controlling cytoskeleton dynamics.
CC       Regulates DNA repair potentially by activating the proapoptotic
CC       pathway when the DNA damage is too severe to be repaired.
CC       Phosphorylates PSMA7 that leads to an inhibition of proteasomal
CC       activity and cell cycle transition blocks.
CC   -!- CATALYTIC ACTIVITY: ATP + a [protein]-L-tyrosine = ADP + a
CC       [protein]-L-tyrosine phosphate.
CC   -!- COFACTOR: Magnesium or manganese.
CC   -!- ENZYME REGULATION: Stabilized in the inactive form by an
CC       association between the SH3 domain and the SH2-TK linker region,
CC       interactions of the amino-terminal cap, and contributions from an
CC       amino-terminal myristoyl group and phospholipids. Activated by
CC       autophosphorylation as well as by SRC-family kinase-mediated
CC       phosphorylation. Activated by RIN1 binding to the SH2 and SH3
CC       domains. Inhibited by imatinib mesylate (Gleevec) which is used
CC       for the treatment of chronic myeloid leukemia (CML). Inhibited by
CC       VX-680, an inhibitor that acts also on imanitib-resistant mutants.
CC   -!- SUBUNIT: Interacts with SORBS1 following insulin stimulation.
CC       Found in a trimolecular complex containing CDK5 and CABLES1.
CC       Interacts with CABLES1 and PSTPIP1. Interacts with ZDHHC16 (By
CC       similarity). Interacts with INPPL1/SHIP2. Interacts with the 14-3-
CC       3 proteins, YWHAB, YWHAE, YWHAG, YWHAH, SFN AND YWHAZ; the
CC       interaction with 14-3-3 proteins requires phosphorylation on Thr-
CC       735 and, sequesters ABL1 into the cytoplasm. Interacts with PSMA7.
CC   -!- INTERACTION:
CC       Q8IZP0:ABI1; NbExp=2; IntAct=EBI-375543, EBI-375446;
CC       Q8CBW3:Abi1 (xeno); NbExp=1; IntAct=EBI-375543, EBI-375511;
CC       Q12979:ABR; NbExp=1; IntAct=EBI-375543, EBI-489922;
CC       Q15027:ACAP1; NbExp=1; IntAct=EBI-375543, EBI-751746;
CC       P02765:AHSG; NbExp=1; IntAct=EBI-375543, EBI-1223374;
CC       O43918:AIRE; NbExp=1; IntAct=EBI-375543, EBI-1753081;
CC       Q13023:AKAP6; NbExp=1; IntAct=EBI-375543, EBI-1056102;
CC       Q9BWW9:APOL5; NbExp=1; IntAct=EBI-375543, EBI-1753592;
CC       O15085:ARHGEF11; NbExp=1; IntAct=EBI-375543, EBI-311099;
CC       Q9ULH1:ASAP1; NbExp=1; IntAct=EBI-375543, EBI-346622;
CC       Q96NS5:ASB16; NbExp=1; IntAct=EBI-375543, EBI-1751918;
CC       Q13315:ATM; NbExp=1; IntAct=EBI-375543, EBI-495465;
CC       Q9UIF9:BAZ2A; NbExp=1; IntAct=EBI-375543, EBI-934890;
CC       Q63767:Bcar1 (xeno); NbExp=1; IntAct=EBI-375543, EBI-1176801;
CC       P34820:BMP8B; NbExp=1; IntAct=EBI-375543, EBI-1752660;
CC       P51587:BRCA2; NbExp=1; IntAct=EBI-375543, EBI-79792;
CC       Q9ULD4:BRPF3; NbExp=1; IntAct=EBI-375543, EBI-1753470;
CC       Q9NUR3:C20orf46; NbExp=1; IntAct=EBI-375543, EBI-1753189;
CC       P13671:C6; NbExp=1; IntAct=EBI-375543, EBI-1753221;
CC       P20810:CAST; NbExp=1; IntAct=EBI-375543, EBI-1268770;
CC       P32239:CCKBR; NbExp=1; IntAct=EBI-375543, EBI-1753137;
CC       Q9Y5K6:CD2AP; NbExp=1; IntAct=EBI-375543, EBI-298152;
CC       P30260:CDC27; NbExp=1; IntAct=EBI-375543, EBI-994813;
CC       O76039:CDKL5; NbExp=1; IntAct=EBI-375543, EBI-1752465;
CC       Q9NYQ7:CELSR3; NbExp=1; IntAct=EBI-375543, EBI-308417;
CC       P49450:CENPA; NbExp=1; IntAct=EBI-375543, EBI-1751979;
CC       Q9H2X0:CHRD; NbExp=1; IntAct=EBI-375543, EBI-947551;
CC       Q14008:CKAP5; NbExp=1; IntAct=EBI-375543, EBI-310585;
CC       P26992:CNTFR; NbExp=1; IntAct=EBI-375543, EBI-743758;
CC       P78357:CNTNAP1; NbExp=1; IntAct=EBI-375543, EBI-1751903;
CC       Q8WX92:COBRA1; NbExp=1; IntAct=EBI-375543, EBI-347721;
CC       P46108:CRK; NbExp=1; IntAct=EBI-375543, EBI-886;
CC       Q7Z408:CSMD2; NbExp=1; IntAct=EBI-375543, EBI-1957312;
CC       O15320:CTAGE5; NbExp=1; IntAct=EBI-375543, EBI-1050253;
CC       Q14999:CUL7; NbExp=1; IntAct=EBI-375543, EBI-308606;
CC       P78329:CYP4F2; NbExp=1; IntAct=EBI-375543, EBI-1752413;
CC       Q9UJV9:DDX41; NbExp=1; IntAct=EBI-375543, EBI-1046350;
CC       Q9UK85:DKKL1; NbExp=1; IntAct=EBI-375543, EBI-1753048;
CC       O14490:DLGAP1; NbExp=1; IntAct=EBI-375543, EBI-1753207;
CC       Q9P1A6:DLGAP2; NbExp=1; IntAct=EBI-375543, EBI-1753397;
CC       O95886:DLGAP3; NbExp=1; IntAct=EBI-375543, EBI-1752541;
CC       Q9Y2H0:DLGAP4; NbExp=1; IntAct=EBI-375543, EBI-722139;
CC       Q92988:DLX4; NbExp=1; IntAct=EBI-375543, EBI-1752755;
CC       Q92874:DNASE1L2; NbExp=1; IntAct=EBI-375543, EBI-1751995;
CC       Q05193:DNM1; NbExp=1; IntAct=EBI-375543, EBI-713135;
CC       P50570:DNM2; NbExp=1; IntAct=EBI-375543, EBI-346547;
CC       Q9UQ16:DNM3; NbExp=1; IntAct=EBI-375543, EBI-1111783;
CC       Q8IZD9:DOCK3; NbExp=1; IntAct=EBI-375543, EBI-1752361;
CC       Q9H1R2:DUSP15; NbExp=1; IntAct=EBI-375543, EBI-1752795;
CC       P52803:EFNA5; NbExp=1; IntAct=EBI-375543, EBI-1753674;
CC       O43281:EFS; NbExp=1; IntAct=EBI-375543, EBI-718488;
CC       Q9Y2J2:EPB41L3; NbExp=1; IntAct=EBI-375543, EBI-310986;
CC       P42566:EPS15; NbExp=1; IntAct=EBI-375543, EBI-396684;
CC       O00254:F2RL2; NbExp=1; IntAct=EBI-375543, EBI-1751853;
CC       Q9BQ89:FAM110A; NbExp=1; IntAct=EBI-375543, EBI-1752811;
CC       O15255:FAM127A; NbExp=1; IntAct=EBI-375543, EBI-954396;
CC       P21333:FLNA; NbExp=1; IntAct=EBI-375543, EBI-350432;
CC       Q14315:FLNC; NbExp=1; IntAct=EBI-375543, EBI-489954;
CC       Q12947:FOXF2; NbExp=1; IntAct=EBI-375543, EBI-1752316;
CC       O15117:FYB; NbExp=1; IntAct=EBI-375543, EBI-1753267;
CC       P06241:FYN; NbExp=1; IntAct=EBI-375543, EBI-515315;
CC       Q9UN86:G3BP2; NbExp=1; IntAct=EBI-375543, EBI-1044298;
CC       Q9UBS5:GABBR1; NbExp=1; IntAct=EBI-375543, EBI-724156;
CC       Q99259:GAD1; NbExp=1; IntAct=EBI-375543, EBI-743184;
CC       P15586:GNS; NbExp=1; IntAct=EBI-375543, EBI-1752200;
CC       Q9Y5Y3:GPR45; NbExp=1; IntAct=EBI-375543, EBI-1751869;
CC       P62993:GRB2; NbExp=1; IntAct=EBI-375543, EBI-401755;
CC       Q9C0E4:GRIP2; NbExp=1; IntAct=EBI-375543, EBI-949557;
CC       O43708:GSTZ1; NbExp=1; IntAct=EBI-375543, EBI-748043;
CC       Q9BZM3:GSX2; NbExp=1; IntAct=EBI-375543, EBI-1753426;
CC       Q9UHL9:GTF2IRD1; NbExp=1; IntAct=EBI-375543, EBI-372530;
CC       Q92664:GTF3A; NbExp=1; IntAct=EBI-375543, EBI-1752104;
CC       Q9UL51:HCN2; NbExp=1; IntAct=EBI-375543, EBI-1751885;
CC       Q9Y3Q4:HCN4; NbExp=1; IntAct=EBI-375543, EBI-1753521;
CC       P06865:HEXA; NbExp=1; IntAct=EBI-375543, EBI-723519;
CC       O43390:HNRNPR; NbExp=1; IntAct=EBI-375543, EBI-713419;
CC       P31273:HOXC8; NbExp=1; IntAct=EBI-375543, EBI-1752118;
CC       Q96AC6:KIFC2; NbExp=1; IntAct=EBI-375543, EBI-724040;
CC       P49916:LIG3; NbExp=1; IntAct=EBI-375543, EBI-1753381;
CC       P50851:LRBA; NbExp=1; IntAct=EBI-375543, EBI-1052167;
CC       P98164:LRP2; NbExp=1; IntAct=EBI-375543, EBI-947916;
CC       Q14767:LTBP2; NbExp=1; IntAct=EBI-375543, EBI-1546118;
CC       Q92918:MAP4K1; NbExp=1; IntAct=EBI-375543, EBI-881;
CC       O60244:MED14; NbExp=1; IntAct=EBI-375543, EBI-394489;
CC       Q9NQ76:MEPE; NbExp=1; IntAct=EBI-375543, EBI-1753293;
CC       P46013:MKI67; NbExp=1; IntAct=EBI-375543, EBI-876367;
CC       Q8NFP9:NBEA; NbExp=1; IntAct=EBI-375543, EBI-723014;
CC       P16333:NCK1; NbExp=1; IntAct=EBI-375543, EBI-389883;
CC       O14513:NCKAP5; NbExp=1; IntAct=EBI-375543, EBI-1752508;
CC       Q9NZQ3:NCKIPSD; NbExp=1; IntAct=EBI-375543, EBI-957585;
CC       Q86SG6:NEK8; NbExp=1; IntAct=EBI-375543, EBI-1752987;
CC       O94856:NFASC; NbExp=1; IntAct=EBI-375543, EBI-1751948;
CC       Q9Y697:NFS1; NbExp=1; IntAct=EBI-375543, EBI-1751791;
CC       P43699:NKX2-1; NbExp=1; IntAct=EBI-375543, EBI-1391923;
CC       Q9UM47:NOTCH3; NbExp=1; IntAct=EBI-375543, EBI-1236377;
CC       Q9HCQ7:NPVF; NbExp=1; IntAct=EBI-375543, EBI-1753111;
CC       O95157:NXPH3; NbExp=1; IntAct=EBI-375543, EBI-1752913;
CC       P20774:OGN; NbExp=1; IntAct=EBI-375543, EBI-1753690;
CC       Q13415:ORC1L; NbExp=1; IntAct=EBI-375543, EBI-374847;
CC       Q9H0X9:OSBPL5; NbExp=1; IntAct=EBI-375543, EBI-1753005;
CC       Q99572:P2RX7; NbExp=1; IntAct=EBI-375543, EBI-1753251;
CC       P23760:PAX3; NbExp=1; IntAct=EBI-375543, EBI-1167564;
CC       Q9UN72:PCDHA7; NbExp=1; IntAct=EBI-375543, EBI-1753660;
CC       Q13087:PDIA2; NbExp=1; IntAct=EBI-375543, EBI-1752525;
CC       P27986:PIK3R1; NbExp=1; IntAct=EBI-375543, EBI-79464;
CC       P98161:PKD1; NbExp=1; IntAct=EBI-375543, EBI-1752013;
CC       P19174:PLCG1; NbExp=1; IntAct=EBI-375543, EBI-79387;
CC       P28340:POLD1; NbExp=1; IntAct=EBI-375543, EBI-716569;
CC       Q08209:PPP3CA; NbExp=1; IntAct=EBI-375543, EBI-352922;
CC       O43900:PRICKLE3; NbExp=1; IntAct=EBI-375543, EBI-1751761;
CC       Q9BXM0:PRX; NbExp=1; IntAct=EBI-375543, EBI-1753064;
CC       P29074:PTPN4; NbExp=1; IntAct=EBI-375543, EBI-710431;
CC       Q13905:RAPGEF1; NbExp=1; IntAct=EBI-375543, EBI-976876;
CC       O76081:RGS20; NbExp=1; IntAct=EBI-375543, EBI-1052678;
CC       Q86UR5:RIMS1; NbExp=1; IntAct=EBI-375543, EBI-1043236;
CC       Q13671:RIN1; NbExp=3; IntAct=EBI-375543, EBI-366017;
CC       Q8TB24:RIN3; NbExp=1; IntAct=EBI-375543, EBI-1570523;
CC       P78345:RPP38; NbExp=1; IntAct=EBI-375543, EBI-366493;
CC       Q9NQC3:RTN4; NbExp=1; IntAct=EBI-375543, EBI-715945;
CC       Q96GP6:SCARF2; NbExp=1; IntAct=EBI-375543, EBI-1752088;
CC       O75326:SEMA7A; NbExp=1; IntAct=EBI-375543, EBI-1753538;
CC       Q9NZV5:SEPN1; NbExp=1; IntAct=EBI-375543, EBI-1751965;
CC       Q15427:SF3B4; NbExp=1; IntAct=EBI-375543, EBI-348469;
CC       P31947:SFN; NbExp=1; IntAct=EBI-375543, EBI-476295;
CC       Q9BYB0:SHANK3; NbExp=1; IntAct=EBI-375543, EBI-1752330;
CC       O75751:SLC22A3; NbExp=1; IntAct=EBI-375543, EBI-1752674;
CC       O60721:SLC24A1; NbExp=1; IntAct=EBI-375543, EBI-1753504;
CC       Q9UMY4:SNX12; NbExp=1; IntAct=EBI-375543, EBI-1752602;
CC       Q15036:SNX17; NbExp=1; IntAct=EBI-375543, EBI-1752620;
CC       O60493:SNX3; NbExp=1; IntAct=EBI-375543, EBI-727209;
CC       Q9Y5X2:SNX8; NbExp=1; IntAct=EBI-375543, EBI-1752557;
CC       Q9BX66:SORBS1; NbExp=2; IntAct=EBI-375543, EBI-433642;
CC       Q07890:SOS2; NbExp=1; IntAct=EBI-375543, EBI-298181;
CC       P08047:SP1; NbExp=1; IntAct=EBI-375543, EBI-298336;
CC       P12931:SRC; NbExp=1; IntAct=EBI-375543, EBI-621482;
CC       P78524:ST5; NbExp=1; IntAct=EBI-375543, EBI-962633;
CC       Q9H5I1:SUV39H2; NbExp=1; IntAct=EBI-375543, EBI-723127;
CC       O15056:SYNJ2; NbExp=1; IntAct=EBI-375543, EBI-310513;
CC       P54274:TERF1; NbExp=1; IntAct=EBI-375543, EBI-710997;
CC       O43493:TGOLN2; NbExp=1; IntAct=EBI-375543, EBI-1752146;
CC       P42167:TMPO; NbExp=1; IntAct=EBI-375543, EBI-455283;
CC       Q9HCM9:TRIM39; NbExp=1; IntAct=EBI-375543, EBI-739510;
CC       Q9UJT2:TSKS; NbExp=1; IntAct=EBI-375543, EBI-852101;
CC       Q9NRJ4:TULP4; NbExp=1; IntAct=EBI-375543, EBI-1753487;
CC       Q8TAS1:UHMK1; NbExp=1; IntAct=EBI-375543, EBI-1753608;
CC       P12018:VPREB1; NbExp=1; IntAct=EBI-375543, EBI-1753454;
CC       Q96RL7:VPS13A; NbExp=1; IntAct=EBI-375543, EBI-1752583;
CC       Q9UMN6:WBP7; NbExp=1; IntAct=EBI-375543, EBI-765774;
CC       Q9Y3S1:WNK2; NbExp=1; IntAct=EBI-375543, EBI-948521;
CC       P63104:YWHAZ; NbExp=1; IntAct=EBI-375543, EBI-347088;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm, cytoskeleton. Nucleus.
CC       Note=Sequestered into the cytoplasm through interaction with 14-3-
CC       3 proteins.
CC   -!- SUBCELLULAR LOCATION: Isoform IB: Nucleus membrane; Lipid-anchor.
CC       Note=The myristoylated c-ABL protein is reported to be nuclear.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=IA;
CC         IsoId=P00519-1; Sequence=Displayed;
CC       Name=IB;
CC         IsoId=P00519-2; Sequence=VSP_004957;
CC         Note=Myristoylated on Gly-2;
CC   -!- TISSUE SPECIFICITY: Widely expressed.
CC   -!- PTM: Phosphorylated by PRKDC (By similarity). DNA damage-induced
CC       activation of c-Abl requires the function of ATM and Ser-446
CC       phosphorylation (By similarity). Phosphorylation on Thr-735 is
CC       required for binding 14-3-3 proteins for cytoplasmic
CC       translocation.
CC   -!- PTM: Isoform IB is myristoylated on Gly-2.
CC   -!- DISEASE: A chromosomal aberration involving ABL1 is a cause of
CC       chronic myeloid leukemia (CML) [MIM:608232]. Translocation
CC       t(9;22)(q34;q11) with BCR. The translocation produces a BCR-ABL
CC       found also in acute myeloid leukemia (AML) and acute lymphoblastic
CC       leukemia (ALL).
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. ABL subfamily.
CC   -!- SIMILARITY: Contains 1 protein kinase domain.
CC   -!- SIMILARITY: Contains 1 SH2 domain.
CC   -!- SIMILARITY: Contains 1 SH3 domain.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/ABL.html";
CC   -!- WEB RESOURCE: Name=CGP resequencing studies;
CC       URL="http://www.sanger.ac.uk/perl/genetics/CGP/cgp_viewer?action=gene&ln=ABL1";
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/abl1/";
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=Abl entry;
CC       URL="http://en.wikipedia.org/wiki/Abl_gene";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M14752; AAA51561.1; -; mRNA.
DR   EMBL; X16416; CAA34438.1; -; mRNA.
DR   EMBL; U07563; AAB60394.1; -; Genomic_DNA.
DR   EMBL; U07563; AAB60393.1; -; Genomic_DNA.
DR   EMBL; U07561; AAB60393.1; JOINED; Genomic_DNA.
DR   EMBL; DQ145721; AAZ38718.1; -; Genomic_DNA.
DR   EMBL; AL359092; CAM45752.1; -; Genomic_DNA.
DR   EMBL; AL161733; CAM45752.1; JOINED; Genomic_DNA.
DR   EMBL; AL161733; CAM45754.1; -; Genomic_DNA.
DR   EMBL; AL161733; CAM45756.1; -; Genomic_DNA.
DR   EMBL; AL359092; CAM45756.1; JOINED; Genomic_DNA.
DR   EMBL; CH471090; EAW87948.1; -; Genomic_DNA.
DR   EMBL; BC117451; AAI17452.1; -; mRNA.
DR   EMBL; S69223; AAD14034.1; -; Genomic_DNA.
DR   IPI; IPI00216969; -.
DR   IPI; IPI00221171; -.
DR   PIR; S08519; TVHUA.
DR   RefSeq; NP_005148.2; -.
DR   RefSeq; NP_009297.2; -.
DR   UniGene; Hs.431048; -.
DR   PDB; 1AB2; NMR; -; A=120-220.
DR   PDB; 1ABL; Model; -; A=65-121.
DR   PDB; 1AWO; NMR; -; A=65-119.
DR   PDB; 1BBZ; X-ray; 1.65 A; A/C/E/G=64-121.
DR   PDB; 1JU5; NMR; -; C=62-121.
DR   PDB; 1OPL; X-ray; 3.42 A; A/B=27-512.
DR   PDB; 1ZZP; NMR; -; A=1007-1130.
DR   PDB; 2ABL; X-ray; 2.50 A; A=57-218.
DR   PDB; 2E2B; X-ray; 2.20 A; A/B=229-515.
DR   PDB; 2F4J; X-ray; 1.91 A; A=229-513.
DR   PDB; 2FO0; X-ray; 2.27 A; A=38-512.
DR   PDB; 2G1T; X-ray; 1.80 A; A/B/C/D=229-512.
DR   PDB; 2G2F; X-ray; 2.70 A; A/B=229-512.
DR   PDB; 2G2H; X-ray; 2.00 A; A/B=229-512.
DR   PDB; 2G2I; X-ray; 3.12 A; A/B=229-512.
DR   PDB; 2GQG; X-ray; 2.40 A; A/B=229-500.
DR   PDB; 2HIW; X-ray; 2.20 A; A/B=230-512.
DR   PDB; 2HYY; X-ray; 2.40 A; A/B/C/D=228-500.
DR   PDB; 2HZ0; X-ray; 2.10 A; A/B=228-497.
DR   PDB; 2HZ4; X-ray; 2.80 A; A/B/C=228-500.
DR   PDB; 2HZI; X-ray; 1.70 A; A/B=229-500.
DR   PDB; 2O88; X-ray; 1.75 A; A/B=64-121.
DR   PDB; 2V7A; X-ray; 2.50 A; A/B=229-512.
DR   PDB; 3CS9; X-ray; 2.21 A; A/B/C/D=229-500.
DR   PDB; 3EG0; X-ray; 2.30 A; A=60-121.
DR   PDB; 3EG1; X-ray; 1.85 A; A/B=60-121.
DR   PDB; 3EG2; X-ray; 1.80 A; A=60-121.
DR   PDB; 3EG3; X-ray; 1.40 A; A=60-121.
DR   PDB; 3EGU; X-ray; 2.25 A; A=60-121.
DR   PDB; 3K2M; X-ray; 1.75 A; A/B=121-232.
DR   PDBsum; 1AB2; -.
DR   PDBsum; 1ABL; -.
DR   PDBsum; 1AWO; -.
DR   PDBsum; 1BBZ; -.
DR   PDBsum; 1JU5; -.
DR   PDBsum; 1OPL; -.
DR   PDBsum; 1ZZP; -.
DR   PDBsum; 2ABL; -.
DR   PDBsum; 2E2B; -.
DR   PDBsum; 2F4J; -.
DR   PDBsum; 2FO0; -.
DR   PDBsum; 2G1T; -.
DR   PDBsum; 2G2F; -.
DR   PDBsum; 2G2H; -.
DR   PDBsum; 2G2I; -.
DR   PDBsum; 2GQG; -.
DR   PDBsum; 2HIW; -.
DR   PDBsum; 2HYY; -.
DR   PDBsum; 2HZ0; -.
DR   PDBsum; 2HZ4; -.
DR   PDBsum; 2HZI; -.
DR   PDBsum; 2O88; -.
DR   PDBsum; 2V7A; -.
DR   PDBsum; 3CS9; -.
DR   PDBsum; 3EG0; -.
DR   PDBsum; 3EG1; -.
DR   PDBsum; 3EG2; -.
DR   PDBsum; 3EG3; -.
DR   PDBsum; 3EGU; -.
DR   PDBsum; 3K2M; -.
DR   ProteinModelPortal; P00519; -.
DR   DIP; DIP-1042N; -.
DR   IntAct; P00519; 180.
DR   MINT; MINT-97648; -.
DR   STRING; P00519; -.
DR   PhosphoSite; P00519; -.
DR   PRIDE; P00519; -.
DR   Ensembl; ENST00000318560; ENSP00000323315; ENSG00000097007.
DR   GeneID; 25; -.
DR   KEGG; hsa:25; -.
DR   UCSC; uc004bzw.1; human.
DR   CTD; 25; -.
DR   GeneCards; GC09P133589; -.
DR   HGNC; HGNC:76; ABL1.
DR   HPA; CAB002686; -.
DR   HPA; HPA027251; -.
DR   HPA; HPA027280; -.
DR   HPA; HPA028409; -.
DR   MIM; 189980; gene.
DR   MIM; 608232; phenotype.
DR   Orphanet; 521; Chronic myeloid leukemia.
DR   PharmGKB; PA24413; -.
DR   HOVERGEN; HBG004162; -.
DR   OMA; GAFRESG; -.
DR   BRENDA; 2.7.10.2; 247.
DR   Pathway_Interaction_DB; lis1pathway; Lissencephaly gene (LIS1) in neuronal migration and development.
DR   Pathway_Interaction_DB; trkrpathway; Neurotrophic factor-mediated Trk receptor signaling.
DR   Pathway_Interaction_DB; pdgfrbpathway; PDGFR-beta signaling pathway.
DR   Pathway_Interaction_DB; telomerasepathway; Regulation of Telomerase.
DR   Reactome; REACT_18266; Axon guidance.
DR   Reactome; REACT_21303; Myogenesis.
DR   DrugBank; DB00171; Adenosine triphosphate.
DR   DrugBank; DB01254; Dasatinib.
DR   DrugBank; DB00619; Imatinib.
DR   NextBio; 79; -.
DR   PMAP-CutDB; P00519; -.
DR   ArrayExpress; P00519; -.
DR   Bgee; P00519; -.
DR   CleanEx; HS_ABL1; -.
DR   Genevestigator; P00519; -.
DR   GermOnline; ENSG00000097007; Homo sapiens.
DR   GO; GO:0005856; C:cytoskeleton; IEA:UniProtKB-SubCell.
DR   GO; GO:0005829; C:cytosol; EXP:Reactome.
DR   GO; GO:0031965; C:nuclear membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005730; C:nucleolus; IDA:MGI.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IDA:UniProtKB.
DR   GO; GO:0003677; F:DNA binding; NAS:UniProtKB.
DR   GO; GO:0000287; F:magnesium ion binding; IDA:UniProtKB.
DR   GO; GO:0030145; F:manganese ion binding; IDA:UniProtKB.
DR   GO; GO:0004715; F:non-membrane spanning protein tyrosine kina...; IEA:EC.
DR   GO; GO:0070064; F:proline-rich region binding; IPI:UniProtKB.
DR   GO; GO:0008022; F:protein C-terminus binding; IPI:UniProtKB.
DR   GO; GO:0017124; F:SH3 domain binding; IPI:UniProtKB.
DR   GO; GO:0030036; P:actin cytoskeleton organization; ISS:UniProtKB.
DR   GO; GO:0007155; P:cell adhesion; IEA:UniProtKB-KW.
DR   GO; GO:0008630; P:DNA damage response, signal transduction re...; TAS:ProtInc.
DR   GO; GO:0006298; P:mismatch repair; TAS:ProtInc.
DR   GO; GO:0018108; P:peptidyl-tyrosine phosphorylation; IDA:UniProtKB.
DR   GO; GO:0051353; P:positive regulation of oxidoreductase activity; IDA:BHF-UCL.
DR   GO; GO:0000115; P:regulation of transcription involved in S p...; TAS:ProtInc.
DR   GO; GO:0007165; P:signal transduction; IEA:InterPro.
DR   InterPro; IPR015015; F-actin_binding.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR000719; Prot_kinase_cat_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR001245; Ser-Thr/Tyr-Pkinase.
DR   InterPro; IPR000980; SH2.
DR   InterPro; IPR001452; SH3_domain.
DR   InterPro; IPR020700; Tyr_kinase_non-rcpt_Abl.
DR   InterPro; IPR020635; Tyr_Pkinase_cat_dom.
DR   InterPro; IPR020685; Tyr_prot_kinase.
DR   InterPro; IPR008266; Tyr_prot_kinase_AS.
DR   Gene3D; G3DSA:3.30.505.10; SH2; 1.
DR   PANTHER; PTHR23256:SF144; Tyr_kinase_non-rcpt_Abl; 1.
DR   PANTHER; PTHR23256; Tyr_prot_kinase; 1.
DR   Pfam; PF08919; F_actin_bind; 1.
DR   Pfam; PF07714; Pkinase_Tyr; 1.
DR   Pfam; PF00017; SH2; 1.
DR   Pfam; PF00018; SH3_1; 1.
DR   PRINTS; PR00401; SH2DOMAIN.
DR   PRINTS; PR00109; TYRKINASE.
DR   SMART; SM00808; FABD; 1.
DR   SMART; SM00252; SH2; 1.
DR   SMART; SM00326; SH3; 1.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF56112; Kinase_like; 1.
DR   SUPFAM; SSF50044; SH3; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
DR   PROSITE; PS50001; SH2; 1.
DR   PROSITE; PS50002; SH3; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ATP-binding; Cell adhesion;
KW   Chromosomal rearrangement; Complete proteome; Cytoplasm; Cytoskeleton;
KW   Kinase; Lipoprotein; Magnesium; Manganese; Membrane; Metal-binding;
KW   Myristate; Nucleotide-binding; Nucleus; Phosphoprotein; Polymorphism;
KW   Proto-oncogene; SH2 domain; SH3 domain; Transferase;
KW   Tyrosine-protein kinase.
FT   CHAIN         1   1130       Tyrosine-protein kinase ABL1.
FT                                /FTId=PRO_0000088050.
FT   DOMAIN       61    121       SH3.
FT   DOMAIN      127    217       SH2.
FT   DOMAIN      242    493       Protein kinase.
FT   NP_BIND     248    256       ATP.
FT   NP_BIND     316    322       ATP.
FT   REGION        1     60       CAP.
FT   MOTIF       381    405       Kinase activation loop.
FT   MOTIF       605    609       Nuclear localization signal (Potential).
FT   COMPBIAS     18     22       Poly-Ser.
FT   COMPBIAS    605    609       Poly-Lys.
FT   COMPBIAS    782   1019       Pro-rich.
FT   COMPBIAS    897    903       Poly-Pro.
FT   ACT_SITE    363    363       Proton acceptor (By similarity).
FT   BINDING     271    271       ATP.
FT   SITE         26     27       Breakpoint for translocation to form BCR-
FT                                ABL oncogene.
FT   MOD_RES      50     50       Phosphoserine.
FT   MOD_RES     185    185       Phosphotyrosine.
FT   MOD_RES     226    226       Phosphotyrosine; by autocatalysis.
FT   MOD_RES     253    253       Phosphotyrosine.
FT   MOD_RES     257    257       Phosphotyrosine.
FT   MOD_RES     264    264       Phosphotyrosine.
FT   MOD_RES     392    392       Phosphothreonine.
FT   MOD_RES     393    393       Phosphotyrosine; by autocatalysis and
FT                                SRC-type Tyr-kinases.
FT   MOD_RES     394    394       Phosphothreonine.
FT   MOD_RES     446    446       Phosphoserine (By similarity).
FT   MOD_RES     469    469       Phosphotyrosine.
FT   MOD_RES     569    569       Phosphoserine.
FT   MOD_RES     613    613       Phosphothreonine.
FT   MOD_RES     620    620       Phosphoserine.
FT   MOD_RES     659    659       Phosphoserine.
FT   MOD_RES     683    683       Phosphoserine.
FT   MOD_RES     718    718       Phosphoserine.
FT   MOD_RES     735    735       Phosphothreonine.
FT   MOD_RES     781    781       Phosphothreonine.
FT   MOD_RES     805    805       Phosphoserine.
FT   MOD_RES     809    809       Phosphoserine.
FT   MOD_RES     814    814       Phosphothreonine.
FT   MOD_RES     844    844       Phosphothreonine.
FT   MOD_RES     852    852       Phosphothreonine.
FT   MOD_RES     855    855       Phosphoserine.
FT   MOD_RES     917    917       Phosphoserine.
FT   MOD_RES     919    919       Phosphoserine.
FT   MOD_RES     936    936       Phosphoserine.
FT   MOD_RES     949    949       Phosphoserine.
FT   MOD_RES     977    977       Phosphoserine.
FT   VAR_SEQ       1     26       MLEICLKLVGCKSKKGLSSSSSCYLE -> MGQQPGKVLGD
FT                                QRRPSLPALHFIKGAGKKESSRHGGPHCNVFVEH (in
FT                                isoform IB).
FT                                /FTId=VSP_004957.
FT   VARIANT      47     47       R -> G (in a lung large cell carcinoma
FT                                sample; somatic mutation).
FT                                /FTId=VAR_032676.
FT   VARIANT     140    140       L -> P (in dbSNP:rs1064152).
FT                                /FTId=VAR_051692.
FT   VARIANT     166    166       R -> K (in a melanoma sample; somatic
FT                                mutation).
FT                                /FTId=VAR_032677.
FT   VARIANT     247    247       K -> R (in dbSNP:rs34549764).
FT                                /FTId=VAR_051693.
FT   VARIANT     706    706       G -> V (in dbSNP:rs34634745).
FT                                /FTId=VAR_025043.
FT   VARIANT     810    810       P -> L (in dbSNP:rs2229071).
FT                                /FTId=VAR_032678.
FT   VARIANT     852    852       T -> P.
FT                                /FTId=VAR_025044.
FT   VARIANT     900    900       P -> S (in dbSNP:rs35266696).
FT                                /FTId=VAR_025045.
FT   VARIANT     968    968       S -> P (in dbSNP:rs1064165).
FT                                /FTId=VAR_051694.
FT   VARIANT     972    972       S -> L (in dbSNP:rs2229067).
FT                                /FTId=VAR_025046.
FT   MUTAGEN     735    735       T->A: Abolishes phosphorylation. Loss of
FT                                binding YWHAS and YWHAZ. Localizes to the
FT                                nucleus. No effect on kinase activity.
FT   CONFLICT    159    159       G -> S (in Ref. 1; AAA51561).
FT   CONFLICT    424    425       AF -> GK (in Ref. 9).
FT   CONFLICT    445    445       L -> R (in Ref. 1; AAA51561).
FT   CONFLICT    459    459       E -> K (in Ref. 1; AAA51561).
FT   CONFLICT    520    520       S -> T (in Ref. 1; AAA51561).
FT   CONFLICT    719    719       A -> V (in Ref. 1; AAA51561).
FT   CONFLICT    837    837       G -> E (in Ref. 2; CAA34438).
FT   CONFLICT    837    837       G -> W (in Ref. 1; AAA51561).
FT   CONFLICT    863    863       G -> R (in Ref. 1; AAA51561).
FT   CONFLICT    894    894       R -> K (in Ref. 1; AAA51561).
FT   CONFLICT    917    919       SPS -> RPG (in Ref. 1; AAA51561).
FT   CONFLICT    952    952       G -> A (in Ref. 1; AAA51561).
FT   CONFLICT    967    968       QS -> HP (in Ref. 1; AAA51561).
FT   CONFLICT    982    982       P -> PL (in Ref. 1; AAA51561).
FT   CONFLICT   1022   1022       Missing (in Ref. 1; AAA51561).
FT   CONFLICT   1045   1045       R -> G (in Ref. 1; AAA51561).
FT   CONFLICT   1103   1103       T -> S (in Ref. 1; AAA51561).
FT   HELIX        49     53
FT   HELIX        58     60
FT   STRAND       65     70
FT   STRAND       87     93
FT   STRAND       97    104
FT   STRAND      107    112
FT   HELIX       113    115
FT   STRAND      116    118
FT   HELIX       122    124
FT   STRAND      128    131
FT   HELIX       134    140
FT   STRAND      142    144
FT   STRAND      148    153
FT   STRAND      155    157
FT   STRAND      161    167
FT   STRAND      170    178
FT   STRAND      184    187
FT   STRAND      192    194
FT   HELIX       195    204
FT   STRAND      209    211
FT   HELIX       239    241
FT   STRAND      242    248
FT   HELIX       249    251
FT   STRAND      254    261
FT   HELIX       262    264
FT   STRAND      266    272
FT   HELIX       280    290
FT   STRAND      301    305
FT   STRAND      307    310
FT   STRAND      312    316
FT   HELIX       323    329
FT   TURN        332    334
FT   HELIX       337    357
FT   HELIX       366    368
FT   STRAND      369    371
FT   HELIX       373    375
FT   STRAND      377    379
FT   STRAND      389    391
FT   HELIX       403    405
FT   HELIX       408    413
FT   HELIX       418    433
FT   HELIX       445    447
FT   HELIX       448    453
FT   HELIX       466    475
FT   HELIX       480    482
FT   HELIX       486    509
FT   TURN        510    512
FT   HELIX      1029   1045
FT   TURN       1046   1048
FT   HELIX      1053   1070
FT   HELIX      1071   1073
FT   HELIX      1080   1097
FT   STRAND     1101   1104
FT   STRAND     1106   1108
FT   HELIX      1115   1128
SQ   SEQUENCE   1130 AA;  122873 MW;  85FE6C1C0E483EA2 CRC64;
     MLEICLKLVG CKSKKGLSSS SSCYLEEALQ RPVASDFEPQ GLSEAARWNS KENLLAGPSE
     NDPNLFVALY DFVASGDNTL SITKGEKLRV LGYNHNGEWC EAQTKNGQGW VPSNYITPVN
     SLEKHSWYHG PVSRNAAEYL LSSGINGSFL VRESESSPGQ RSISLRYEGR VYHYRINTAS
     DGKLYVSSES RFNTLAELVH HHSTVADGLI TTLHYPAPKR NKPTVYGVSP NYDKWEMERT
     DITMKHKLGG GQYGEVYEGV WKKYSLTVAV KTLKEDTMEV EEFLKEAAVM KEIKHPNLVQ
     LLGVCTREPP FYIITEFMTY GNLLDYLREC NRQEVNAVVL LYMATQISSA MEYLEKKNFI
     HRDLAARNCL VGENHLVKVA DFGLSRLMTG DTYTAHAGAK FPIKWTAPES LAYNKFSIKS
     DVWAFGVLLW EIATYGMSPY PGIDLSQVYE LLEKDYRMER PEGCPEKVYE LMRACWQWNP
     SDRPSFAEIH QAFETMFQES SISDEVEKEL GKQGVRGAVS TLLQAPELPT KTRTSRRAAE
     HRDTTDVPEM PHSKGQGESD PLDHEPAVSP LLPRKERGPP EGGLNEDERL LPKDKKTNLF
     SALIKKKKKT APTPPKRSSS FREMDGQPER RGAGEEEGRD ISNGALAFTP LDTADPAKSP
     KPSNGAGVPN GALRESGGSG FRSPHLWKKS STLTSSRLAT GEEEGGGSSS KRFLRSCSAS
     CVPHGAKDTE WRSVTLPRDL QSTGRQFDSS TFGGHKSEKP ALPRKRAGEN RSDQVTRGTV
     TPPPRLVKKN EEAADEVFKD IMESSPGSSP PNLTPKPLRR QVTVAPASGL PHKEEAGKGS
     ALGTPAAAEP VTPTSKAGSG APGGTSKGPA EESRVRRHKH SSESPGRDKG KLSRLKPAPP
     PPPAASAGKA GGKPSQSPSQ EAAGEAVLGA KTKATSLVDA VNSDAAKPSQ PGEGLKKPVL
     PATPKPQSAK PSGTPISPAP VPSTLPSASS ALAGDQPSST AFIPLISTRV SLRKTRQPPE
     RIASGAITKG VVLDSTEALC LAISRNSEQM ASHSAVLEAG KNLYTFCVSY VDSIQQMRNK
     FAFREAINKL ENNLRELQIC PATAGSGPAA TQDFSKLLSS VKEISDIVQR
//
